Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 inhibitor plus nimotuzumab and gemcitabine/cisplatin for first-line metastatic nasopharyngeal carcinoma
ChiCTR2300073467Phase 2Recruiting
- Sponsor
- Dongguan People's Hospital
- Start
- Jun 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab, gemcitabine, cisplatin and capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Dongguan People's Hospital. Primary endpoint: One-year progression-free survival rate. Started Jun 2023; status: recruiting.
02
Drugs
nimotuzumabgemcitabinecisplatincapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2300073467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073467.